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A concise route for the synthesis of Fingolimod is reported. Starting from n-octylbenzene and 3-nitropropionic acid,
a sequence of reactions consisting of Friedel-Crafts acylation, reduction, and double Henry reaction, followed by
hydrogenation were applied to prepare Fingolimod with a yield of 31%, and an overall atom economy of 82.7%.
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Fingolimod (1, FTY-720) was first synthesized in 1992
[1,2]. It is an immunomodulating drug, and was approved
for treating multiple sclerosis(MS) in 2010. Fingolimod is a
sphingosine 1-phosphate receptor modulator precursor
that becomes active in vivo following phosphorylation by
sphingosine kinase 2 to form Fingolimod-phosphate. This
phosphate moiety binds to extracellular G protein-coupled
receptors, sphingosine 1-phosphates and prevents the re-
lease of lymphocytes from lymphoid tissue thus preventing
them from contributing to an autoimmune reaction. This
process could lead to a neural protection and restoration
process, and can reduce MS recurrence rate, slow down
the progression of damage, reduce intracranial magnetic
resonance imaging (MRI), the number of lesions, and re-
duce the severity of the lesions [3,4].
Structurally, Fingolimod could be divided into three
parts: the hydrophobic n-octyl side chain (A), the planar
aromatic ring with a two carbon linker (B), and the
hydrophilic amino-alcohol terminal (C, Figure 1).
To date, several synthetic routes for Fingolimod have
been reported [5-15]. However, these synthetic methods
were unsuitable to industrial scale-up mainly due to the
involvement of multiple steps and dangerous chemicals
such as lithium aluminium hydride (LAH).
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reproduction in any medium, provided the oist’s interest. During our investigation for the application
of 3-nitropropionic acid as synthetic building block, we
envisioned that compound 4 (Scheme 1) could be a key
intermediate in the synthesis of Fingolimod. This com-
pound could be obtained by other synthetic routes re-
ported in literatures [16]. Herein, we report a concise
synthesis of Fingolimod, which is economically sound
and easy to operate.
Treatment of the commercially available n-octylbenzene
(2) with 3-nitropropanoyl chloride under AlCl3 gave com-
pound 4 with good yield (85%). The gem-hydroxylmethyl
moiety was introduced to compound 4 on the alpha car-
bon to form intermediate 7b, and then the nitro group
and carbonyl group were reduced simultaneously in one
single step. However, the reaction of compound 4 with
formaldehyde (or equivalent) was messy, and no clean 7b
could be isolated. We ascribed the failure to the presence
of the carbonyl group, which might cyclize with the hy-
droxyl group generated in the Henry reaction, or form a
cyclopropanol when it was intra-molecularly attacked by
the α-carbon anion. Therefore, we tried to reduce the car-
bonyl group before the Henry reaction. Thus, treatment of
compound 4 with triethylsilane and TFA gave compound 6
with high yield (98%). Compound 6, which contained only
one acidic site, could be easily converted to compound 7a
by a double Henry type reaction by treatment with formal-
dehyde under basic condition [1]. To complete the synthe-
sis of Fingolimod (1), the nitro group in compound 7a was
reduced to amine, followed by a salt formation.
As described above, compound 6 [6,17] was the key
intermediate in the synthesis of Fingolimod. We also
tried an alternative way to prepared it. In this route, aOpen Access article distributed under the terms of the Creative Commons
org/licenses/by/4.0), which permits unrestricted use, distribution, and






Figure 1 Structure of Fingolimod.
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of the relatively more expensive 3-nitropropionic acid.
Thus, compound 3 was obtained by treatment of n-
octylbenzene with 3-bromopropanoyl chloride under the
presence of AlCl3. However, the direct displacement of
the Br group to a NO2 group in compound 3 to form
compound 4 using sodium nitrate and DMF failed, be-
cause the reason might be that the Br is a good leaving
group, and the elimination of HBr to form an enone ra-
ther the nucleophilic substitution was preferred for com-
pound 3. To avoid the elimination reaction, a two-step
operation was adopted to convert compound 3 to 6 by
first reducing the carbonyl group by triethylsilane to
form compound 5, and then a SN2 displacement reac-
tion to yield 6. The yield of the SN2 displacement reac-
tion was low under un-optimized conditions because
some nitrite product was isolated.Scheme 1 Synthesis of Fingolimod.In summary, a concise route for the synthesis of Fin-
golimod was reported from commercially available n-
octylbenzene in 4 steps with an overall yield of 31%, and
the atom economy for the whole route was 82.7%.
Description of additional material
3-Bromo-1-(4-octylphenyl)propan-1-one (3)
To a flame-dried 500 mL 4-necked flask, was charged
n-octylbenzene 24.39 g (0.128 mol), hexane 158 mL,
and the reaction mixture was cooled to 5°C. To this
mixture, a solution of 3-bromopropanyl chloride 25.0 g
(0.146 mol) was added dropwise, followed by addition
of AlCl3 19.55 g (0.147 mol) in portion to control the reac-
tion temperature under 10°C. The reaction mixture was
allowed to stir at 0°C for 0.5 h, room temperature for 1 h,
then reflux for 0.5 h. The reaction mixture was poured
into a water-crushed-ice solution with vigorous stirring,
the precipitate was collected and washed with water. The
filtrate was extracted by ethyl acetate, and the combined
organic phase was concentrated. The solid was combined
and re-crystallized in petroleum ether to afford an off-
white solid 31 g. yield:74.3%. M.p.:38–40°C. 1H NMR
(400 MHz, CDCl3) δ 7.11 (m, 4H), 3.32 (t, J = 4.0 Hz, 2H),
3.13 (t, J = 4.0 Hz, 2H), 2.56 (t, J = 4.0 Hz, 2H), 1.59
(m, 2H), 1.23-1.35 (m, 10H), 0.87 (t, J = 6.8 Hz, 3H); 13C
NMR (CDCl3) δ 198.8, 143.1, 132.6, 128.4, 128.1, 42.8,
36.0, 31.8, 31.3, 29.8, 29.4, 29.2, 26.5, 22.5, 14.3.
1-Bromo-3-(4-octylphenyl)propane (5)
To a flam-dried 250 mL 4-necked flask, was added
7.92 g (24.4 mmol) of compound 3 and 18.6 mL TFA.
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of 5.65 g (48.7 mmol) of triethylsilane was added drop-
wise. The reaction mixture was allowed to stir at 10°C
for 30 min, and then at room temperature for 4 h. The
reaction mixture was poured into water with crushed-ice
under vigorous stirring, and the pH was adjusted to 8 by
NaHCO3. The mixture was extracted by petroleum ether
100 mL × 3, and the organic phase was combined, washed
with brine, dried by Na2SO4, filtered, and concentrated to
afford a yellow liquid, which was subjected to flash
chromatography (EA:Hex = 1:8) to afford a colorless oil
(7.46 g. Yield: 98.4%). 1H NMR (400 MHz, CDCl3) δ
7.12 (s, 4H), 3.18 (t, J = 8.0 Hz, 2H), 2.90 (t, J = 4.0 Hz,
2H), 2.57 (t, J = 4.0 Hz, 2H), 1.54-1.67 (m,4H), 1.24-
1.34 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR
(CDCl3) δ 136.1, 133.6, 128.4, 128.0, 36.1, 34.4, 33.4,
31.9, 31.3, 29.7, 29.4, 29.2, 28.8, 22.5, 14.1.
Nitro-3-(4-octylphenyl)propane (6)
Method A: To a mixture of 9.59 g (30.8 mmol) of com-
pound 5 and 44 mL of DMF, was added 8.47 g
(122.8 mmol) of NaNO2 at 0°C. The reaction mixture was
allowed to stir at 0°C for 0.5 h, then at room temperature
for 6 h. The reaction mixture was poured into 200 mL of
iced-water, extracted with petroleum ether 100 mL × 3.
The organic layer was combined, washed with brine, dried
by Na2SO4, filtered, and concentrated to afford a yellow li-
quid, which was purified by flash chromatography (EA:
Hex = 1:8) to afford a colorless oil (3.00 g. Yield: 35.1%).
Method B: By the same procedures as described in making
compound 5 using compound 4 and triethylsilane as reac-
tants. 1H NMR (400 MHz CDCl3) δ 7.07-7.13 (m, 4H),
4.36 (t, J = 7.2 Hz, 2H), 2.69 (t, J =7.5 Hz, 2H), 2.57 (t, J =
4.0 Hz, 2H), 2.31 (m, 2H), 1.55-1.61 (m, 2H), 1.24-1.34
(m, 10H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3) δ
139.8, 139.1, 128.4, 128.2, 89.5, 63.3, 36.1, 31.9, 31.3,
29.7, 29.4, 29.2, 28.83, 28.81, 22.5, 14.1.
3-Nitro-1-(4-octylphenyl)propan-1-one (4)
Compound 4 was prepared by the same method as
described in the preparation of compound 3 using n-
octylbenzene and 3-nitropropanoyl chloride (making
from 3-nitropropanoic acid [18] and thionyl chloride)
as starting material. Yield: 85%. 1H NMR (400 MHz
CDCl3) δ 7.07-7.13 (m, 4H), 4.36 (t, J = 7.2 Hz, 2H),
2.69 (t, J =7.5 Hz, 2H), 2.57 (t, J = 4.0 Hz, 2H), 2.31
(m, 2H), 1.55-1.61 (m, 2H), 1.24-1.34 (m, 10H), 0.88
(t, J = 7.0 Hz, 3H); 13C NMR (CDCl3) δ 139.8, 139.1,
128.4, 128.2, 89.5, 63.3, 36.1, 31.9, 31.3, 29.7, 29.4,
29.2, 28.83, 28.81, 22.5, 14.1.
2-Nitro-2-(4-octylphenylethyl)propane-1,3-diol (7a)
To a four-necked round bottom of flask, was added 0.6 g
(2.17 mmol) of compound 6 and 10 mL 1,4-dioxane, then3.3 g of polyformaldehyde and 4 drops of TEA. The reac-
tion was allowed to stir at 70°C for 4 h till all starting ma-
terial was consumed. The solvent was removed under
reduced pressure, and the residue was purified by flash
chromatography (EA:Hex = 1:3) to afford the title com-
pound as a white solid. Yield: 41.1%, M.P.: 99–101°C. 1H
NMR( 400 MHz, CDCl3) δ: 7.09 (d, J = 8.0 Hz, 2H),
7.06 (d, J = 8.0 Hz, 2H), 4.24 (d, J = 12.0 Hz, 2H), 4.06
(d, J = 12.0 Hz, 2H), 2.53-2.57 (m, 4H), 2.16-2.20 (m,
2H), 1.54-1.59 (m, 2H), 1.24-1.34 (m, 10H), 0.84 (t, J=
6.0 Hz, 3H); 13C NMR (CDCl3) δ 136.1, 133.6, 128.4, 128.0,
75.1, 36.1, 33.4, 31.9, 31.3, 29.7, 29.4, 29.2, 28.8, 22.5, 14.1.
2-Amino-2-(4-octylphenylethyl)propane-1,3-diol HCl (1)
To a 100 mL reactor, was added 0.3 g (0.89 mmol) of
compound 7a, 10 mL of ethanol, and 30 mg of 10%
Pd/C. The reaction mixture was allowed to stir at
room temperature for 15 h under a 0.3 MPa hydrogen-
ation condition. The reaction was filtered through a
pad of Celite, and washed with ethanol. The combine
filtrate was concentrated under reduced pressure to af-
ford a white solid, which was treated with 20 mL of
saturated HCl in ethanol, and the plate solid (0.28 g)
was collected as the salt form of the title compound.
Yield : 92%. M.p.: 106 ~ 108°C (lit.107-108°C). 1H NMR
(400 MHz,CDCl3) δ: 7.08 (s, 4H, Ar-H), 3.62 (s, 2H), 3.54
(s, 2H), 2.52-2.60 (m, 8H), 1.69-1.70 (m, 2H), 1.57 (m, 2H),
1.20-1.25 (m, 10H), 0.87 (t, J = 6.0 Hz, 3H); 13C NMR
(CDCl3) δ 139.8, 139.1, 128.3, 128.2, 61.1, 60.5, 34.9, 33.4,
31.4, 31.2, 29.0, 28.83, 28.81, 28.1, 22.2, 14.1.
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